LONGEVA.

LC600: evidence on adverse reactions

A levocarnitine medicine label describes severe allergic reactions after intravenous administration, mostly in dialysis patients. Postmarketing reports also include seizures with oral or intravenous use. These reports cannot establish event frequencies. [1]

These findings concern medicinal levocarnitine preparations. They do not establish safety of a particular LC600 laboratory-powder batch or equivalence to a medicine. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Severe allergic reactionsPatients, mostly on dialysis; medicinal levocarnitine intravenously (official medicine label)Described in the label; these reports cannot establish event frequencies[1]
SeizuresPostmarketing reports, levocarnitine orally or intravenouslyReported after marketing; frequency cannot be established[1]

References

  1. Baxter Healthcare Corporation (2026). Levocarnitine injection, solution: official Baxter label.